Biodel Inc.'s phase II study of BIOD-123, an investigational ultra-rapid-acting mealtime insulin, in patients with type 1 diabetes, has met the primary endpoint of non-inferiority for HbA1c relative to Eli Lilly's blockbuster diabetes medication Humalog.
Don't waste another minute! Join us for the 20th Annual "DFM Invitational" benefiting the Diabetes Foundation of Mississippi. We invite you to enjoy what has become the premier golfing event of the season!
You received this email because you subscribed to Yahoo! Alerts. Use this link to unsubscribe from this alert. To change your communications preferences for other Yahoo! business lines, please visit your Marketing Preferences. To learn more about Yahoo!'s use of personal information, including the use of web beacons in HTML-based email, please read our Privacy Policy. Yahoo! is located at 701 First Avenue, Sunnyvale, CA 94089.
No comments:
Post a Comment